GlassScriptPhysician profile
Edwin F Adams
NPI 1437155793
$5,513.54
in general payments reported to CMS, 2019-2025
21 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $319 · 2021: $237 · 2022: $903 · 2023: $673 · 2024: $1,365 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,437.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $819.27 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $803.39 | 2019-2025 | Acuvue |
| Abbvie INC. | $657.73 | 2022-2025 | Lumigan, Vuity |
| Alcon Vision LLC | $637.94 | 2020-2025 | Rocklatan, Total30, Dailies Total1 |
| Glaukos Corporation | $609.41 | 2019-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Bausch & Lomb Americas INC. | $330.86 | 2022-2025 | Infuse, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $248.49 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $241.25 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $158.69 | 2024-2025 | Acthar |
| Harrow Eye, LLC | $150.71 | 2024-2025 | Vevye |
| Coopervision INC. | $147.81 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $138.16 | 2024 | Tecnis Iol |
| Oyster Point Pharma, INC. | $118.86 | 2023-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $116.95 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $100.00 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.51 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.95 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $43.44 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $36.95 | 2021 | |
| Biotissue Holdings INC. | $18.04 | 2023 | |
| Eyevance Pharmaceuticals LLC | $15.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.